GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
1k
c/cagrilintide·posted 4 months ago by u/bpc_sceptic

the co-agonism question that gets asked weekly, answered properly

Caution Slow Clap ×4 The Quiet One ×3

Long-ish post, sorry. tl;dr at the bottom.

I have been tracking cagrilintide against eGFR for 15 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here.

Caveats up front: one person, one lab, one assay, no control, and I changed my training in the middle of it, which was stupid.

tl;dr: probably real, definitely smaller than the threads imply, and not worth reorganising your week around.

1,127 up / 125 down90% upvoted50 commentsid 19myj618 Mar 2026

50 comments

27 in this archive, depth 4

best — the order this archive was captured in

u/kavya_kravchenko108 points·4 months ago

Rodent or human data?

replysharereportpermalink
u/amylin_amyMOD34 points·4 months ago

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

replysharereportpermalink
u/noor_ivaturi27 points·4 months ago

amylin receptor distribution is different from GLP-1

replysharereportpermalink
u/nadia_fonseca8 points·4 months ago

Small correction: the trial was 16 weeks, not 26. Does not change your point but people will quote it.

replysharereportpermalink
load more comments (1) →
u/lukas_vermeulen45 points·4 months ago

REDEFINE readouts are phase 8 data

replysharereportpermalink
u/hana_pereira11 points·4 months ago

long-acting amylin is co-agonism, different satiety profile

replysharereportpermalink
u/bpc_scepticOPresearch peptides-7 points·4 months ago

REDEFINE phase 3 readouts are interesting but 3 person satiety is different from 3 trial satiety.

replysharereportpermalink
u/ahmed_fonseca12 points·4 months ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink
u/incretin_ivypharmacology51 points·4 months ago

Yeah, amylin is doing different work than GLP-1.

replysharereportpermalink
u/sulphur_burps_sue37 points·4 months ago

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/bpc_scepticOPresearch peptides22 points·4 months ago

tendon and co-agonism literature in rodents is interesting

replysharereportpermalink
u/nadia_bakker7 points·4 months ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/sulphur_burps_sue3 points·4 months ago

long-acting amylin is co-agonism, different satiety profile

replysharereportpermalink
u/bpc_scepticOPresearch peptides22 points·4 months ago

The research community is small on cagrilintide. Forum lore changes faster than data.

replysharereportpermalink
u/slow_logbook_notes3025 points·4 months ago

REDEFINE phase 24 readouts are interesting but 24 person REDEFINE is different from 24 trial REDEFINE.

replysharereportpermalink
u/throwaway_44b111 points·4 months ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
[deleted]9 points·4 months ago

[deleted]

replysharereportpermalink
u/zeynep_zielinski9 points·4 months ago

Strongly agree. REDEFINE is phase 5, not final.

replysharereportpermalink
u/milan_mensah18 points·4 months ago
IANAD and neither is anyone upvoting this
replysharereportpermalink
u/liv_dumitru14 points·4 months ago·edited

amylin receptor distribution is different from GLP-1

replysharereportpermalink
u/zeynep_zielinski6 points·4 months ago

The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does REDEFINE.

replysharereportpermalink
u/protein_first_pnutrition4 points·4 months ago

This is correct. The co-agonism is real.

replysharereportpermalink
u/laila_dumitru12 points·4 months ago

Mechanistically the bit that matters is cagrilintide. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/emeka_chowdhury8 points·4 months ago

Are we talking amylin or GLP-1 here?

replysharereportpermalink
u/liv_dumitru10 points·4 months ago
batch number?
replysharereportpermalink
u/nadia_fonseca4 points·4 months ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.